Oncolytics Biotech (ONCY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Oct, 2026Executive summary
Annual meeting scheduled for November 19, 2026, at 4:00 p.m. ET; voting deadline is November 18, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Shareholders will vote on director elections, auditor ratification, an advisory executive compensation vote, and an advisory vote on say-on-pay frequency; the board recommends a three-year frequency.
Board of directors and corporate governance
Seven director nominees: Jared Kelly, Bernd R. Seizinger, Deborah M. Brown, James T. Parsons, Jonathan Rigby, Patricia S. Andrews, and Stephen Glover.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Oncolytics Biotech
- Seven director seats and four voting matters headline a proxy featuring a new CEO and auditor.ONCY
Proxy filing - Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources.ONCYQ2 2026
- Pelareorep shows robust survival gains in breast cancer, with pivotal trials and funding underway.ONCY2024 Cantor Fitzgerald Global Healthcare Conference
- Pelareorep delivers durable survival benefits in GI cancers, outperforming standard therapies.ONCYInvestor presentation
- Promising GI cancer data and new patent strategies position pelareorep for major milestones.ONCYJefferies Global Healthcare Conference 2026
- Q1 2026 net loss rose to $9.2M; cash at $5.5M; funding needed for continued operations.ONCYQ1 2026
- Pelareorep delivers robust efficacy and safety in GI cancers, advancing toward pivotal approvals.ONCYInvestor presentation
- Pelareorep nearly doubled survival in breast cancer and is advancing toward pivotal trials.ONCYQ3 2024
- Pelareorep advanced in breast and pancreatic cancer with strong cash and key data expected in H2 2024.ONCYQ2 2024